GW reports survival data in Phase II GBM study

GW Pharmaceuticals plc (NASDAQ:GWPH) said data from a Phase II trial showed that THC:CBD (GW42002:GW42003) significantly improved one-year overall survival vs. placebo as an add-on therapy to treat glioblastoma multiforme. Among the study's 21 patients, the candidate led to a one-year OS rate of 83% vs. 53% for placebo (p=0.042). The product combines tetrahydrocannabinol and cannabidiol.

According to ClinicalTrials.gov, one-year OS rate and six-month progression-free survival (PFS) rate are among the trial's secondary endpoints. On a conference call Tuesday, GW management declined to give specific PFS data, but said they were consistent with the OS data. The study's primary endpoint evaluated safety...